Clinical Trials Logo

Filter by:
NCT ID: NCT05942937 Recruiting - HCV Clinical Trials

National Prisons Hepatitis Education Project: Research Evaluation

HepPEd
Start date: September 4, 2023
Phase: N/A
Study type: Interventional

The National Prisons Hepatitis Education Program (HepPEd Program) is a national, prison-based hepatitis C health literacy education program for healthcare providers, correctional officers, and people in prison. The HepPEd Program aims to improve the public health literacy of the prison sector regarding hepatitis C in prisons. The HepPEd: Research Evaluation aims to evaluate the impact of the HepPEd Program on HCV testing and treatment uptake amongst people incarcerated in Australian prisons, as well as changes in knowledge, attitudes, and capabilities of healthcare providers, correctional officers, and people in prison. The study is a controlled before and after study being conducted in 3-6 correctional centres in Australia.

NCT ID: NCT05942911 Recruiting - Clinical trials for Rheumatoid Arthritis

Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

CHAPPII
Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

The goal of this randomised, double-blind, placebo-controlled Phase II clinical trial is to assess the safety and effect of of IHL-675A in rheumatoid arthritis patients on pain, and function according to RAPID-3. 128 volunteers will be enrolled and randomised to one of four treatments (32 subjects per treatment). Each treatment will be self-administered twice daily for 24 weeks. The four treatments are: - Treatment 1 - IHL-675A - Treatment 2 - CBD - Treatment 3 - HCQ - Treatment 4 - Placebo

NCT ID: NCT05941949 Recruiting - Healthy Clinical Trials

Nutritional Supplement's Effects on Cognition

Start date: July 5, 2023
Phase: N/A
Study type: Interventional

This is a prospective, placebo controlled study, examining the effects of dietary supplement's effects on cognition and confirming safety.

NCT ID: NCT05939414 Recruiting - Clinical trials for Oligometastatic Prostate Cancer (OMPC)

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

PSMA-DC
Start date: March 12, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).

NCT ID: NCT05938946 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults

Start date: August 30, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.

NCT ID: NCT05938270 Recruiting - Prostate Cancer Clinical Trials

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

ASCERTAIN
Start date: September 21, 2023
Phase: Phase 1
Study type: Interventional

A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN)

NCT ID: NCT05937581 Recruiting - Clinical trials for Complement Deficiencies

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Start date: September 28, 2023
Phase: Phase 1
Study type: Interventional

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

NCT ID: NCT05936359 Recruiting - Clinical trials for Myeloproliferative Neoplasms

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Start date: September 25, 2023
Phase: Phase 1
Study type: Interventional

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

NCT ID: NCT05935124 Recruiting - Adenoma Colon Clinical Trials

A Randomized Comparison Between White Light Endoscopy (WLE) and Bright Narrow Band Imaging (B-NBI) in the Diagnosis of Right Sided Colonic Polyps in Asymptomatic Subjects Undergoing Screening Colonoscopy

WLEvsB-NBI
Start date: August 1, 2015
Phase: N/A
Study type: Interventional

A randomized controlled crossover study to determine if narrow band imaging or white light endoscopy is superior in detecting right colonic polyps in average risk subjects undergoing screening colonoscopy

NCT ID: NCT05935098 Recruiting - Solid Tumor Clinical Trials

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Start date: August 21, 2023
Phase: Phase 1
Study type: Interventional

This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advanced or metastatic solid tumors.